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Abstract
Background: Various studies reported remarkable high incidence rates of depression in cancer patients compared
with the general population. Pancreatic cancer is still one of the malignancies with the worst prognosis and
therefore it seems quite logical that it is one of the malignancies with the highest incidence rates of major
depression.
However, what about the scientific background of this relationship? Is depression in patients suffering from pan-
creatic cancer just due to the confrontation with a life threatening disease and its somatic symptoms or is depres-
sion in this particular group of patients a feature of pancreatic cancer per se?
Discussion: Several studies provide evidence of depression to precede the diagnosis of pancreatic cancer and
some studies even blame it for its detrimental influence on survival. The immense impact of emotional distress on
quality of life of cancer patients enhances the need for its early diagnosis and adequate treatment. Knowledge
about underlying pathophysiological mechanisms is required to provide the optimal therapy.
Summary: A review of the literature on this issue should reveal which are the facts and what is myth.
Background
Various studies have demonstrated the immense impact
of psychological distress on life quality and illness trajec-
tory in pancreatic cancer patients. Moreover, Bultz et al.
entitled emotional distress “the sixth vital sign in cancer
care” [1,2]. Accordingly they requested health care pro-
viders to attach no less importance to the monitoring of
emotional distress than to the monitoring of “tradi-
tional” vital signs such as blood pressure or heart rate.
Patients may benefit from early recognition and ade-
quate treatment of emotional burden or even depression
as documented in several studies[3]. However it is still a
matter of debate whether individual psychological cop-
ing strategies have significant impact on overall survival
in cancer patients [4].
Pancreatic cancer in particular is one of the tumor
entities with a strikingly high incidence of depression as
well as one of those with the worst prognosis. Is this
just a coincidence or a sign of a reciprocal interaction?
What is the impact of psyche on cancer mortality? To
address this issue we reviewed published data on pan-
creatic cancer related depression for evidence of a
relationship between psychological distress and the
course of this disease.
Discussion
Pancreatic cancer and depression
A comprehensive study by Hinz et al. has reported that
the prevalence of anxiety and depression in cancer
patients is nearly as twice as high as in the general
population [5]. This observation is consistent with data
from the large nord-trondelag health study by Stordal et
al. [6]. Several preceding studies reported similar results
but a few did not show elevated depression scores
related to cancer [7-10]. Regarding the diversity of stu-
dies on this topic any inconsistency in findings can be
mainly attributed to low sam p l es i z e ,t h el a c ko fd i f f e r -
entiation by gender, age and time since diagnosis, treat-
ment and other methodological flaws as well [5,10-12].
Those studies evaluating different tumor entities sepa-
rately have remarkably high depression rates associated
with specific tumor types in common. In particular
patients with pancreatic, lung, oropharyngeal and breast
cancer are seriously affected by emotional burden and
major depression [10,11,13,14]. In this respect pancrea-
tic cancer is the tumor entity with the highest incidence
rate of depression among all other tumors of the diges-
tive system [15-17].
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cancer and major depression has been known for more
than 70 years [18]. The initial description dates back to
Yaskin in 1931 [19]. His report on the association
between pancreatic cancer and the triad of anxiety,
depression and “sense of impending doom” was the ori-
gin of several ensuing studies [18-20]. In 1967 Fras et al.
reviewed the available “original contributions, which
mentioned mental symptoms as a part of symptomatol-
ogy of carcinoma of the pancreas”. In this study depres-
sion was diagnosed in 76% of the patients with
pancreatic cancer and only in 20% of the patients with
colon cancer. This investigation was made prior to sur-
gery and more than 50% of the patients with pancreatic
cancer reported psychological symptoms, up to 43
months before somatic complaints [15]. This aroused a
debate about “mental symptoms as an aid for early diag-
nosis of pancreatic cancer” [21]. Jacobsson et al. found
initial depression in 14% of patients who were after-
wards diagnosed with cancer of the pancreas but only in
4% of patients with subsequent diagnosis of gastric can-
cer [22]. A similar study by Joffe et al. 1986 reported
severe depression in over half the patients who were
finally diagnosed with pancreatic cancer but none in the
patients with gastric cancer [23]. Some case reports
inscribe psychological symptoms like panic or anxiety as
a harbinger of the subsequent tumor diagnosis [24,25].
Unexpected high incidence rates were confirmed by a
study in 1993 showing symptoms of depression in 71%
of the examined pancreatic cancer patients and “anxi-
ety-related symptoms” in 48% of the patients [26]. In
the aforementioned comprehensive review by Massie et
al. the prevalence of depression in pancreatic cancer was
between 33 and 50% [10].
For most of the studies have investigated patients
recently diagnosed with cancer, the possibility of recall
b i a sh a sb et ob ec o n s i d e r e d. Holland et al. employed
self-assessment questionnaires to assess depression,
anxiety, fatigue and mood swings in patients with
advanced cancer [16]. Finally patients with pancreatic
cancer had higher self-ratings of depression than
patients with other advanced abdominal tumors. In con-
trast a prospective study by Labori et al. which
employed self-report measures as the Edmonton Symp-
tom Assessment Scale (ESAS) also noted relatively low
levels of depression in patients with advanced pancreatic
carcinoma, but the small sample size of this study and
the large standard deviations put the definite impact of
the result up for discussion [27,28]. These methodologi-
cal limitations complicate the final appraisal of the avail-
able studies. Another challenge is the differentiation
between major depression and the “quite normal” psy-
chological distress of patients coping with cancer diag-
nosis. So there is indeed a demand for an appropriate
instrument to identify cancer related, cancer specific
depression.
Diagnosis of depression-screening tools
The reliability of any data on the incidence of depres-
sion in cancer patients is highly depended on the appro-
priate choice of the assessment tool. The respective tool
has to be suitable not only for differentiation between
depression and “quite normal” psychological distress of
patients coping with cancer diagnosis but also for avoid-
ing misattribution of symptoms of the tumor disease to
depression [20]. Unfortunately studies on the predictive
v a l u eo ft h ed i f f e r e n ts c r e e n i n gt o o l sa r es p a r s e[ 2 9 , 3 0 ] .
The basic structures of the established depression
assessment tools are mainly diagnostic interviews,
patient self-report forms or observer ratings [31]. In
general, the classification of depression as a variety of
affective disorders complies with the Diagnostic and Sta-
tistical Manual of Mental D i s o r d e r sD S M - I Ve d i t e d
1994 by American Psychiatric Association (correspond-
ing to ICD-10). The current version DSM-IV-TR was
published July 2000, a revised version, the DSM-V is
being developed at present.
The anxiety disorders interview schedule for DSM-IV,
a structured clinical interview, may be employed to
assess a range of disorders going through different items
[29,32]. The DSM-IV-classification was often questioned
to be adequate for application in cancer patients. The
advantage of structured clinical interviews is undoubted,
but they have to be conducted by skilled staff and there-
fore require enormous amounts of resources [31].
Patient self-report screening inventories are brief
enough and therefore more useful in routine application
in cancer patients [30]. Furthermore, self-report forms
are supposed to be more sensitive to identify significant
functional impairment during follow up [29]. Therefore,
it is often recommended to use self-report forms as a
first step to identify depression followed by a structured
interview in the emerging cases [31]. Up to the present
time a variety of assessment instruments have been
developed and the different forms were employed in
multiple studies. The most common ones applied in
cancer patients are referred to below.
The Hamilton Rating Scale for Depression (HAMD)
has been a standard instrument for peer assessment of
depression’s severity since 1970 [33]. Lin et al. most
recently used the HAMD-24 as the rating scale for depres-
sion to screen patients with gastrointestinal tumors [17].
HAMD-24 contains 24 items which are recalled within the
modified HAMD version of 1985 [34]. But HAMD as well
as CPRS (Comprehensive Psychopathological Rating
Scale) or MADRS (Montgomery-Asberg Depression Rat-
ing Scale) are in fact no adequate diagnostic instruments
for depression but measures of illness severity and it is still
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mary identification of major depression [11,35-37]. In can-
cer patients diagnosis of depression requires special effort
because somatic symptoms of depression like fatigue,
anorexia and weight loss are quite common in malignan-
cies. Therefore the focus has to be on evaluation of psy-
chological and cognitive symptoms like hopelessness, loss
of ambition, anhedonia or suicidal ideation [18,38,39]. To
meet these demands assessment instruments like the Dis-
tress Thermometer, the Brief Symptom Inventory
(BSI), the Symptom Checklist 90-R (SCL-90)o rt h ePro-
blem Common Checklist have been designed
[9,14,28,40]. The currently most established self-assess-
ment instruments are the Becks Depression Inventory
(BDI)a n dt h eHospital Anxiety and Depression Scale
(HADS) questionnaire. The BDI has been developed for
clinical implementation of psychiatric patients to rate
severity of depression symptoms and may be combined
with the Beck Hopelessness Scale (BHS) to assess cogni-
tive aspects of depression [41]. But it comprises some
somatic items which may cause false positive results by
the influence of underlying disease and concomitant ther-
apy [31]. The Hospital and Anxiety Depression Scale
(HADS) has been designed to avoid in particular an
immoderate influence of somatic symptoms in screening
for depression [11]. Its validity and reliability in cancer
patients has been demonstrated in several studies [31].
Pathophysiological aspects of cancer related depression
There are two pivotal questions to address. First, is
depression a specific feature of cancer or could it be
traced to the disease’s severe concomitant symptoms
and its fatal prognosis? - Second, is depression itself a
promoter of tumor development or are pathophysiologi-
cal changes due to cancer responsible for the high inci-
dence of depression?
One possible approach to the evident bidirectional
relationship between depression and pancreatic cancer
is to regard the extent of psychological distress patients
experience being faced with such fatal diagnosis. For
pancreatic cancer patients the impact of medical, psy-
chological and social factors is generally more severe
than for patients with other intestinal cancers [18].
Another approach to the origin of cancer-related
depression comprises the research of possible pathophy-
siological mechanisms.
Some authors ascribe cancer related depression to
paraneoplastic limbic enceph a l i t i s[ 4 2 , 4 3 ]-b u tt oc o n -
firm this diagnosis a range of neuropathological tests are
necessary. Symptoms of paraneoplastic limbic encephali-
tis often precede cancer diagnosis as depression pre-
cedes pancreatic cancer [20]. Almost 50% of pancreatic
cancer patients show depressive symptoms in advance
of their tumor diagnosis [18,20,26]. In a study with
strikingly high incidence of depression in pancreatic
cancer Lin et al. reported no statistically significant dif-
ference in patients knowing diagnosis or not [17].
Among these patients development of depression was
independent of the awareness of “impending doom”.
Accordingly it is still under discussion whether pancrea-
tic cancer induces depression or whether depression
enhances the risk of tumor development [20,44].
In this debate a dysregulated immune response is sup-
posed to be the causal link between depression and can-
cer. Animal models indicate that proinflammatory
cytokines can elicit “depression-like” symptoms [12,45].
In pancreatic cancer patients indeed increased levels of
several cytokines such as IL-6, IL-18 and TNF-alpha can
be found. These factors may have impact on the
hypothalamic-pituitary-adrenal (HPA) axis and the CRF
(corticotropin-releasing factor). Some authors assume
t h i sp a t h w a yt ob et h ec a u s ef o rp a t h o l o g i cr e s u l t si n
the dexamethason suppression test, in analogy to a para-
neoplastic symptom. Elevated IL-6 plasma levels in par-
ticular seem to be associated with major depression in
pancreatic cancer patients and tumor cells can influence
production of serotonin receptor antibodies active in
central nervous system [23,46-49].
Antidepressant therapy - an essential part of supportive
care
Depression is one of the crucial factors impairing life
quality of cancer patients. Accordingly early and ade-
quate antidepressant treatment is an essential compo-
nent of all-embracing supportive care. Management of
depression requires sufficient pain control and psycholo-
gical support as well as use of antidepressants [50]. Any
possible organic causes of depression like metabolic dis-
order, infections, drug side effects (i.e. chemotherapeutic
substances) or brain radiation should be considered
before administration of pharmacologic therapy [18,39].
Clinical trials have shown the efficacy of various anti-
depressants to be comparable [18,39,50]. The choice of
the appropriate antidepressant substance should be
determined by the main target symptoms referring to
the patient’s current medical problems and the side
effect profile [50]. Among the variety of antidepressants
and antipsychotic drugs a selection of the most estab-
lished ones is listed below.
Tricyclic antidepressants are the most commonly
administered drugs [11,18,51]. They may even be effec-
tive as concomitant therapy for patients with neuro-
pathic pain, insomnia and specific cholinergic
symptoms. There is an unexplained smaller therapeutic
range of tricyclic agents in cancer patients which is to
be considered [18]. Due to increased serotonin levels in
pancreatic cancer selective serotonin re-uptake inhibi-
tors (SSRIs) may be effective as a kind of “targeted
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depressant, demonstrated higher sustained remission
rate than amitriptylin and more rapid onset in several
studies. Therefore mirtazapine is applicable even in
elderly patients and recommended for those with a
short life expectancy. Besides it is assumed to have
effects on pain, nausea, emesis and appetite loss [52-54].
Amisulpride as an atypical antipsychotic enhances dopa-
minergic transmission in the frontal cortex and limbic
areas. Concomitant treatment during chemotherapy
achieved significant reduction of depressive symptoms
with minimal side effects [55]. Patients with prevalent
symptoms of anxiety receive better treatment response
with benzodiazepines [18,38,48]. But benzodiazepines
may increase psychomotoric slowing and fatigue which
is a very general complaint of cancer patients. Hence
different drugs have been tested to decrease weakness.
Among various psychostimulants methylphenidate is the
most established, but firstly the results of the different
trials are inconsistent and secondly tolerance may
develop [18,20,39]. Finally some authors refer to current
guidelines which suggest psychostimulants “to be rea-
sonable to consider for severe fatigue” [56].
Beyond pharmacologic treatment of depression sup-
portive psychotherapy including teaching coping strate-
gies plays an important role in handling cancer related
depression. Even if it is regarded as an essential treat-
ment approach restricted life expectancy has to be taken
in account when constituting the type of psychotherapy
or supportive counseling [11,18,39].
Depression and cancer mortality
The relationship between affective disorders and mortal-
ity has been in the scientific focus for more than 60
years. Kerr et al. reported 1969 an “increased mortality
rate from physical disease in patients with affective dis-
orders, particularly from carcinoma” [57]. They also
noticed remarkably high rates of pancreatic cancer and
lung carcinoma among these patients. The following
decades numerous investigat i o n so nd e p r e s s i o ni nc a n -
cer patients have been conducted. High prevalence rates
of depression particularly in patients suffering from
tumor entities with worse prognosis like pancreatic can-
cer led to the crucial question for the impact of depres-
sion on mortality. The history of depression in cancer
patients has been linked to worse overall survival rates
due to impaired immune response and higher rates of
suicide in some but not all studies [11,38,58]. In a retro-
spective analysis of survival data of 258 patients by Shei-
bani-Rad et al. pancreatic cancer associated depression
did not affect survival [59].
Vice versa the effect of antidepressant therapies on
mortality was investigated. First descriptions of the
influence of psychotherapeutic interventions on the
survival of tumor patients were published over 30 years
ago. Some studies reported that group therapies led to
prolonged survival rates in the participating patients
[60]. They were sharply criticized for methodical flaws
and bias like the poor survival data of the control group
but the question for the linkage between psychological
factors and the course of cancer remained.
Several reviews and meta-analyses examined the sup-
posed linkage critically. In 2002 Petticrew et al. reviewed
a selection of prospective observational studies to judge
the impact of psychological coping styles on the survival
from or the recurrence of cancer. Consistent evidence
for the often cited bilateral relationship could hardly be
asserted. The authors stated the positive results to be
“confined to small and methodologically flawed studies”.
In agreement with other authors they assumed influen-
tial publication bias [61].
Nevertheless more and more trials on this topic have
been conducted in recent years. Almost all report on
the high incidence of depressive symptoms and conse-
quently, the significant impact on survival. In 2007 Steel
et. al performed a noteworthy prospective study to
establish a meditational model of depression, immunity
and survival in patients with hepatobiliary carcinoma
[58]. As soon as the paper was published a counterstate-
ment put it up for discussion due to a variety of con-
founding factors including the small sample size [62].
Currently a meta-analysis on depression and cancer
mortality by Pinquart et al. reassessed the reliability of
results depending on varying study characteristics.
Finally “the associations between depression and mortal-
ity persisted after controlling for confounding medical
variables”, but the authors emphasize the demand for
further research also [4,61].
Summary
The phenomenon of cancer related depression has been
observed and investigated in every possible way over the
last decades. Most of the studies demonstrate strikingly
high incidence rates of depression in cancer patients parti-
cularly among those with fatal prognosis like pancreatic
cancer. Moreover, a recently published trial complains
about a lack of attention to psychological distress in pan-
creatic cancer patients [28] - although the immense
impact of depression on quality of life has been established
and meanwhile assessment of life quality is highly standar-
dized. Comparing pancreatic cancer patients with and
without depression a significant deterioration of life qual-
ity has been demonstrated. In clinical studies patients with
pancreatic cancer showed most significant impairment in
scores of physical, emotional and cognitive functioning
with a special impact on social functioning. The score of
symptom scales in particular fatigue and pain was signifi-
cantly higher in the pancreatic cancer group comparing it
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tion between pain and depression is well documented
[38,41]. It is still under discussion whether the presence of
depression increases the risk of chronic pain per se or suf-
fering from chronic pain evolves major depression itself
[11], but chronic pain is undoubtedly a crucial factor in
judging quality of life [50].
Concerning the linkage between depression and the
course of cancer and survival a lot of studies were con-
ducted. Several of them described a strong relationship
between depression and mortality and some could not
detect a linkage at all. With regard to comprehensive
meta-analyses there is a tendency for a correlation
between higher levels of depressive symptoms and ele-
vated mortality, but judgment of available study results is
confined to small sample sizes and various confounding
factors [4,61]. Investigations concerning the pathophysio-
logical background inspired the hope for a better under-
standing of the correlation between somatic and
psychiatric illness and the possible impact on mortality.
Disorders in endocrinological and immunological path-
ways have been supposed to be responsible for the influ-
ence of negative psychological aspects on survival but
these biochemical changes have even been assumed to
elicit depressive reactions themselves [63,64]. It is a feasi-
ble aspect that the correlation between emotional disor-
ders and illness trajectory is confounded by the often
poor clinical state of the patients. The poor clinical state
itself is associated with a poor prognosis and its somatic
symptoms are highly correlated with depressive reactions
[65,66]. So the employed assessment tools for depression
should minimize the influence of clinical symptoms.
In summary there is no final explanation for the linkage
between pancreatic cancer, depression and survival and
t h e r ei sn or e l i a b l ee v i d e n c et h a tp s y c h o l o g i c a lc o p i n g
styles may definitely influence survival or recurrence of
cancer [61]. Therefore cancer patients should not be
blamed of worsening their situation when not participating
in group interventions or psychotherapeutic treatment
[62]. But review of the data published so far confirms the
utmost importance of paying attention to depressive reac-
tions in cancer patients and care for early adequate treat-
ment because the impact on quality of life is assured and
for patients suffering from a malignancy with such a poor
prognosis like pancreatic cancer improving quality of life
has to be the major therapeutic goal. Actually dealing with
this topic the frontiers between reality and myth are mer-
ging and further investigation is required to determine the
extraordinary correlation of psychological and pathophy-
siological findings in pancreatic cancer.
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